Transplant Outcomes and Rates of Graft-vs-Host Disease for FLT3-ITD Acute Myeloid Leukemia by Graft Source in the Era of Posttransplant Gilteritinib Maintenance (SOHO 2026) - Sep 1, 2026 - Abstract #AML-1029; Location: LEVEL 3, HALL B3; "Patients: Patients were included if they received reduced-intensity conditioning allo-HCT in CR from 2016 to 2024 with posttransplant cyclophosphamide. Patients with TP53 mutation and receiving post-HCT sorafenib were excluded... In FLT3-ITD AML, BM grafts were associated with less GVHD and improved GRFS vs PBSC grafts, without compromising relapse or survival. GVHD was a more frequent reason for noninitiation of gilteritinib among PBSC recipients, suggesting graft source may influence the feasibility of FLT3 inhibitor maintenance, a hypothesis warranting further evaluation. AML: acute myeloid leukemia, BM: bone marrow, CI: confidence interval, CR: complete remission, FLT3: fms related receptor tyrosine kinase 3, GVHD: graft-vs-host disease, HR: hazard ratio, ITD: internal tandem duplication, OS: overall survival, PBSC: peripheral blood stem cell, RFS: relapse-free survival, TP53: tumor protein p53."
Clinical • Post-transplantation • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3 • NPM1 • TP53
|
|
Joseph Mort MD; Mark Levis MD PhD; Alex Ambinder MD,MPH
|